Literature DB >> 9492845

Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc.

T Turner1, W H Jackson, G R Pettit, A Wells, A S Kraft.   

Abstract

BACKGROUND: Dolastatin 10 is an anticancer peptide isolated from the sea hare, Dolabela auricularia, which is currently in phase I trials.
METHODS: The effects of dolastatin 10 on the DU-145 human prostate cancer cell line were studied both in tissue culture and in athymic nude mice. In tissue culture, after dolastatin 10 treatment, cell cycle kinetics were measured using propidum iodide, apoptosis was estimated using the TUNEL assay, and tubulin architecture studied by direct immunofluorescence.
RESULTS: At concentrations of 1 nM (IC50 = 0.5 nM), dolastatin 10 completely inhibited the growth in tissue culture of human prostate cancer DU-145 cells. Growth inhibition was correlated with the arrest of these cells in G2/M and alpha-tubulin depolymerization. In athymic mice at a dose of 5 micrograms every 4 days i.p., dolastatin 10 blocked the diaphragmatic invasion of DU-145 tumor cells.
CONCLUSIONS: Dolastatin 10 is a novel marine-derived compound with activity in the treatment of human prostate cancer in animals. The mechanism of action of this agent involves tubulin depolymerization but not the induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9492845     DOI: 10.1002/(sici)1097-0045(19980215)34:3<175::aid-pros4>3.0.co;2-h

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

1.  Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers.

Authors:  Hedy L Kindler; Peter K Tothy; Robert Wolff; Richard A McCormack; James L Abbruzzese; Sridhar Mani; Kurombi T Wade-Oliver; Everett E Vokes
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

Review 2.  Reptiles as Promising Sources of Medicinal Natural Products for Cancer Therapeutic Drugs.

Authors:  Soon Yong Park; Hyeongrok Choi; Jin Woong Chung
Journal:  Pharmaceutics       Date:  2022-04-16       Impact factor: 6.525

Review 3.  Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.

Authors:  Franco Dosio; Paola Brusa; Luigi Cattel
Journal:  Toxins (Basel)       Date:  2011-07-14       Impact factor: 4.546

Review 4.  Bioactive Peptide of Marine Origin for the Prevention and Treatment of Non-Communicable Diseases.

Authors:  Ratih Pangestuti; Se-Kwon Kim
Journal:  Mar Drugs       Date:  2017-03-09       Impact factor: 5.118

Review 5.  Therapeutic Potential of Marine Peptides in Prostate Cancer: Mechanistic Insights.

Authors:  Salman Ahmed; Waqas Alam; Philippe Jeandet; Michael Aschner; Khalaf F Alsharif; Luciano Saso; Haroon Khan
Journal:  Mar Drugs       Date:  2022-07-22       Impact factor: 6.085

Review 6.  Marine Cyanobacteria as Sources of Lead Anticancer Compounds: A Review of Families of Metabolites with Cytotoxic, Antiproliferative, and Antineoplastic Effects.

Authors:  Benjamín Robles-Bañuelos; Lorena María Durán-Riveroll; Edgar Rangel-López; Hugo Isidro Pérez-López; Leticia González-Maya
Journal:  Molecules       Date:  2022-07-27       Impact factor: 4.927

Review 7.  Marine cyanobacteria compounds with anticancer properties: a review on the implication of apoptosis.

Authors:  Margarida Costa; João Costa-Rodrigues; Maria Helena Fernandes; Piedade Barros; Vitor Vasconcelos; Rosário Martins
Journal:  Mar Drugs       Date:  2012-09-28       Impact factor: 6.085

Review 8.  Axonal Transport and Neurodegeneration: How Marine Drugs Can Be Used for the Development of Therapeutics.

Authors:  Joseph A White; Rupkatha Banerjee; Shermali Gunawardena
Journal:  Mar Drugs       Date:  2016-05-19       Impact factor: 5.118

Review 9.  Marine Antitumor Peptide Dolastatin 10: Biological Activity, Structural Modification and Synthetic Chemistry.

Authors:  Gang Gao; Yanbing Wang; Huiming Hua; Dahong Li; Chunlan Tang
Journal:  Mar Drugs       Date:  2021-06-24       Impact factor: 5.118

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.